Navigation Links
New Treatment Rivals Chemotherapy For Lymphoma, Study Finds

The future of cancer treatment - targeted radiotherapy, on a cellular scale. Antibodies coupled to radioactive isotopes specifically seek out, bind to and kill cancerous cells. Provided that you can find something different on the cell surface between normal and cancerous cells; this is not as easy as it sounds.

A new form of treatment for lymphoma that takes a fraction of the time of traditional chemotherapy with fewer side effects caused tumors to shrink in 95 percent of patients, a new study by researchers at the University of Michigan Comprehensive Cancer Center found.

Patients with advanced-stage follicular lymphoma ?a cancer generally considered incurable ?who had not been previously treated with any other form of therapy received a single course of treatment with the Bexxar therapeutic regimen, a radioactive antibody injected into the bloodstream that targets and kills cancer cells. Of the 76 patients enrolled in the study, 95 percent responded to the treatment and 75 percent had a complete response, meaning no evidence of cancer remained. More than three-quarters of patients with a complete remission were disease-free after five years.

Results of the study appear in the Feb. 3 New England Journal of Medicine.

"The results of this treatment, which essentially takes only one week to complete, rival any kind of treatment that's been used for follicular lymphoma, including chemotherapy regimens that take months to complete. It's very well-tolerated by patients and we saw complete remission in the majority of patients lasting for years," says lead study author Mark Kaminski, M.D., director of the Leukemia/Lymphoma Program and the Multidisciplinary Lymphoma Clinic at the U-M Comprehensive Cancer Center.

Kaminski and his colleague Richard Wahl (formerly at U-M and now at Johns Hopkins University) developed the Bexxar regimen, which received approval from the U.S. Food and Drug Administration in June 2003 to treat foll
'"/>

Source:University Of Michigan Health System


Page: 1 2 3

Related biology news :

1. Discovery Could Lead To Novel Approaches In HIV Treatment
2. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
3. Effective Cancer Treatments Follow The Clock
4. Protein Discovery Could Unlock The Secret To Better TB Treatment
5. Natural Killers Could Lead to New Hepatitis Treatments
6. FDA Approves New Treatment for Chronic Hepatitis B
7. Study Finds Moderate Hypothermia A Safe Treatment For Traumatic Brain Injury In Kids
8. Drug Offers Alternative to Surgical Treatment After Miscarriage
9. Treatments have same target, different responses for lung cancer patients with genetic mutation
10. Minimally Invasive Cancer Treatments Highlighted
11. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Treatment Rivals Chemotherapy For Lymphoma Study Finds

(Date:8/20/2014)... honeybees grows to about 4,000 members, it triggers an ... of a special type of comb used for rearing ... the Department of Neurobiology and Behaviour at Cornell University, ... cycle of honeybee colonies. The results are published in ... . , Reproduction isn,t always a honeybee colony,s ...
(Date:8/19/2014)... decrease China,s increasing caesarean section rate, suggests a new ... International Journal of Obstetrics and Gynaecology (BJOG) . , ... in the world. Of 16 million babies born in ... rate is not known, the current Chinese language literature ... ranging from 36% to 58%. However, before the 1980s, ...
(Date:8/19/2014)... It,s not a monkey. It,s not a lemur. It,s ... Meet the Philippine tarsier: a tiny, adorable and downright "cool" ... animals that Americans are familiar with," said Rafe Brown, curator-in-charge ... giant eyes and ears; an extremely cute, furry body; a ... interesting expanded fingers and toe tips that look a bit ...
Breaking Biology News(10 mins):Worker bees 'know' when to invest in their reproductive future 2Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3
... University may make a difference one day at the gas ... organic compound on earth, has enough energy to be the ... break it down could be devised. Cellulose is a cell ... assistant professor in Kansas State University,s Division of Biology, has ...
... available in Spanish . Hake is ... and, nevertheless, resists stock depletion relatively well. At times nature ... Nerea Goikoetxea, a researcher at Azti-Tecnalia, has been witness to ... European hake population, observing which environment has favoured the species ...
... While highly potent embryonic stem cells are often the subject of ... we age, our stem cells are less pliant and less able ... breakthrough treatments for disease. An exception to this can be ... lines the inside of our mouths. These cells do not seem ...
Cached Biology News:Learning secrets of world's most common organic compound driving research for biofuels 2Hake population has withstood overfishing, thanks to the warming of the sea 2Hake population has withstood overfishing, thanks to the warming of the sea 3'Open wide' for new stem cell potential 2'Open wide' for new stem cell potential 3
(Date:8/21/2014)... St. Louis, MO (PRWEB) August 21, 2014 ... premier, full service biopharmaceutical contract development and manufacturing ... selected by Progenics Pharmaceuticals, Inc., an oncology company ... targeting and treating cancer, to manufacture the anti-prostate ... Progenics’ PSMA ADC product candidate. Under the ...
(Date:8/20/2014)... inventions licensed to biotechnology firms has revealed early ... these roadblocks, the researchers suggest that better communication ... could lead to faster commercialization down the road. ... made in university laboratories and licensed to biotechnology ... which have a high failure rate. But a ...
(Date:8/20/2014)... 20, 2014 High performance computing ... the most complete climate and Earth system model ... change issues. , Eight national laboratories, including ... National Center for Atmospheric Research, four academic institutions ... Other participating national laboratories include Argonne, Brookhaven, Lawrence ...
(Date:8/20/2014)... Not long ago, it was more or ... late in the development cycle – even after the ... suggest that, like many things GxP, expectations for early ... multiple drug sponsors have been required by authorities to ... phase I/II. It’s not only clinical trial material containers ...
Breaking Biology Technology:Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... Sept. 16 Martek Biosciences (Nasdaq: MATK ) today ... Directors. , , Mr. Pernock brings ... products, having served from 1994 to 2009 in a variety of ... companies. In his most recent executive role, Mr. Pernock served as ...
... , HEIDELBERG, Germany, September 16 ... Proteomics Approach Identifies new,Potential Drug Targets in Wnt Pathway , ... "Tankyrase inhibition,stabilizes axin and antagonizes Wnt signalling"** is now available ... how Cellzome,s quantitative chemical proteomics,platform was used to identify a ...
... , , SAN ... ) announced today that Kevin Gorman, President and Chief Executive Officer ... Sciences Conference in New York. , , ... p.m. Eastern Time (ET)/10:00 a.m. Pacific Time (PT). The presentation ...
Cached Biology Technology:Martek Announces Addition to Its Board of Directors 2Cellzome Technology Used to Unravel Novel Regulatory Mechanism in Cancer Signaling Pathway 2
cDNA Size Fractionation Columns offer an efficient and convenient method for size-fractioning double-stranded cDNA....
... delivery of buffer and fixative results ... version. In Vivo Manual Perfusion Fixation ... of buffer and fixative results in ... use and clean--Complete system with everything ...
... your 35mm dish without transferring to ... has separate openings for solution inflow ... of the liquid level in the ... entering the chamber. An adjustable metal ...
Sf21 cells derived from Spodoptera frugiperda ovarian cells are recommended for high-level production of recombinant proteins. Higher expression levels of some proteins are seen due to the larger ce...
Biology Products: